KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.73
+7.49 (38.90%)
Apr 29, 2026, 11:07 AM EDT - Market open
KalVista Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Dec '24 Dec 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 |
| Market Capitalization | 1,369 | 816 | 685 | 419 | 479 | 291 | |
| Market Cap Growth | 161.24% | 19.24% | 63.55% | -12.59% | 64.29% | -6.71% | |
| Enterprise Value | 970 | 790 | 538 | 289 | 411 | 128 | |
| Last Close Price | 19.24 | 16.15 | 13.77 | 8.47 | 11.35 | 8.53 | |
| PS Ratio | 13.39 | 11.09 | - | - | - | - | |
| PB Ratio | - | -301.11 | 7.18 | - | 2.32 | 1.81 | |
| P/TBV Ratio | - | - | 7.18 | - | 2.32 | 1.81 | |
| EV/Sales Ratio | 13.17 | 10.73 | - | - | - | - | |
| Debt / Equity Ratio | -104.83 | -104.83 | 1.18 | - | 0.04 | 0.05 | |
| Net Debt / Equity Ratio | 5.90 | 5.90 | -1.14 | - | -0.98 | -0.88 | |
| Net Debt / EBITDA Ratio | 0.10 | 0.10 | 0.58 | - | 1.45 | 1.28 | |
| Net Debt / FCF Ratio | 0.13 | 0.13 | 0.71 | - | 2.28 | 1.85 | |
| Quick Ratio | 5.43 | 5.43 | 5.22 | - | 9.70 | 11.18 | |
| Current Ratio | 5.58 | 5.58 | 5.35 | - | 9.90 | 11.46 | |
| Return on Equity (ROE) | - | - | -121.50% | - | -68.90% | -53.69% | |
| Return on Assets (ROA) | - | - | -48.34% | - | -41.94% | -35.80% | |
| Return on Capital Employed (ROCE) | -59.80% | -59.80% | -91.40% | - | -66.10% | -65.90% | |
| Earnings Yield | -16.67% | -20.13% | -26.80% | -39.58% | -26.45% | -31.88% | |
| FCF Yield | -12.68% | -15.31% | -22.40% | - | -18.64% | -26.23% | |
| Buyback Yield / Dilution | -12.32% | -8.49% | -3.53% | -30.37% | -31.89% | -13.96% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.